138 related articles for article (PubMed ID: 31580073)
1. Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.
Findlay AD; Foot JS; Buson A; Deodhar M; Jarnicki AG; Hansbro PM; Liu G; Schilter H; Turner CI; Zhou W; Jarolimek W
J Med Chem; 2019 Nov; 62(21):9874-9889. PubMed ID: 31580073
[TBL] [Abstract][Full Text] [Related]
2. The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis.
Schilter H; Findlay AD; Perryman L; Yow TT; Moses J; Zahoor A; Turner CI; Deodhar M; Foot JS; Zhou W; Greco A; Joshi A; Rayner B; Townsend S; Buson A; Jarolimek W
J Cell Mol Med; 2019 Mar; 23(3):1759-1770. PubMed ID: 30536539
[TBL] [Abstract][Full Text] [Related]
3. Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis.
Yao Y; Findlay A; Stolp J; Rayner B; Ask K; Jarolimek W
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628342
[TBL] [Abstract][Full Text] [Related]
4. Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice.
Leiva O; Ng SK; Matsuura S; Chitalia V; Lucero H; Findlay A; Turner C; Jarolimek W; Ravid K
Int J Hematol; 2019 Dec; 110(6):699-708. PubMed ID: 31637674
[TBL] [Abstract][Full Text] [Related]
5. Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.
Chen W; Yang A; Jia J; Popov YV; Schuppan D; You H
Hepatology; 2020 Aug; 72(2):729-741. PubMed ID: 32176358
[TBL] [Abstract][Full Text] [Related]
6. Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
Rowbottom MW; Bain G; Calderon I; Lasof T; Lonergan D; Lai A; Huang F; Darlington J; Prodanovich P; Santini AM; King CD; Goulet L; Shannon KE; Ma GL; Nguyen K; MacKenna DA; Evans JF; Hutchinson JH
J Med Chem; 2017 May; 60(10):4403-4423. PubMed ID: 28471663
[TBL] [Abstract][Full Text] [Related]
7. 2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
Smithen DA; Leung LMH; Challinor M; Lawrence R; Tang H; Niculescu-Duvaz D; Pearce SP; Mcleary R; Lopes F; Aljarah M; Brown M; Johnson L; Thomson G; Marais R; Springer C
J Med Chem; 2020 Mar; 63(5):2308-2324. PubMed ID: 31430136
[TBL] [Abstract][Full Text] [Related]
8. Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships.
Leung L; Niculescu-Duvaz D; Smithen D; Lopes F; Callens C; McLeary R; Saturno G; Davies L; Aljarah M; Brown M; Johnson L; Zambon A; Chambers T; Ménard D; Bayliss N; Knight R; Fish L; Lawrence R; Challinor M; Tang H; Marais R; Springer C
J Med Chem; 2019 Jun; 62(12):5863-5884. PubMed ID: 31070916
[TBL] [Abstract][Full Text] [Related]
9. Lysyl oxidases: from enzyme activity to extracellular matrix cross-links.
Vallet SD; Ricard-Blum S
Essays Biochem; 2019 Sep; 63(3):349-364. PubMed ID: 31488698
[TBL] [Abstract][Full Text] [Related]
10. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
[TBL] [Abstract][Full Text] [Related]
11. Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse.
Nguyen LT; Saad S; Shi Y; Wang R; Chou ASY; Gill A; Yao Y; Jarolimek W; Pollock CA
Sci Rep; 2021 Jun; 11(1):12437. PubMed ID: 34127702
[TBL] [Abstract][Full Text] [Related]
12. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.
Vadasz Z; Kessler O; Akiri G; Gengrinovitch S; Kagan HM; Baruch Y; Izhak OB; Neufeld G
J Hepatol; 2005 Sep; 43(3):499-507. PubMed ID: 16023247
[TBL] [Abstract][Full Text] [Related]
13. The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin.
Kim YM; Kim EC; Kim Y
Mol Biol Rep; 2011 Jan; 38(1):145-9. PubMed ID: 20306300
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
Hajdú I; Kardos J; Major B; Fabó G; Lőrincz Z; Cseh S; Dormán G
Bioorg Med Chem Lett; 2018 Oct; 28(18):3113-3118. PubMed ID: 30098867
[TBL] [Abstract][Full Text] [Related]
15. Aminoalkylaziridines as substrates and inhibitors of lysyl oxidase: specific inactivation of the enzyme by N-(5-aminopentyl)aziridine.
Nagan N; Callery PS; Kagan HM
Front Biosci; 1998 May; 3():A23-6. PubMed ID: 9563974
[TBL] [Abstract][Full Text] [Related]
16. Lysyl oxidase as a potential therapeutic target.
Rodríguez C; Rodríguez-Sinovas A; Martínez-González J
Drug News Perspect; 2008 May; 21(4):218-24. PubMed ID: 18560621
[TBL] [Abstract][Full Text] [Related]
17. Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy.
Stangenberg S; Saad S; Schilter HC; Zaky A; Gill A; Pollock CA; Wong MG
Sci Rep; 2018 Jun; 8(1):9423. PubMed ID: 29930330
[TBL] [Abstract][Full Text] [Related]
18. Extracellular Processing of Lysyl Oxidase-like 2 and Its Effect on Amine Oxidase Activity.
Okada K; Moon HJ; Finney J; Meier A; Mure M
Biochemistry; 2018 Dec; 57(51):6973-6983. PubMed ID: 30499665
[TBL] [Abstract][Full Text] [Related]
19. LOXL2 Inhibitors and Breast Cancer Progression.
Ferreira S; Saraiva N; Rijo P; Fernandes AS
Antioxidants (Basel); 2021 Feb; 10(2):. PubMed ID: 33669630
[TBL] [Abstract][Full Text] [Related]
20. A molecular role for lysyl oxidase in breast cancer invasion.
Kirschmann DA; Seftor EA; Fong SF; Nieva DR; Sullivan CM; Edwards EM; Sommer P; Csiszar K; Hendrix MJ
Cancer Res; 2002 Aug; 62(15):4478-83. PubMed ID: 12154058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
